Ligand- and Structure-Based Virtual Screening in Drug Discovery

Abstract

The virtual screening (VS) is an important tool used in the modern drug discovery process to identify new leads and drug-like molecules for therapeutic interventions. With the rapid advancements in the computational hardware supported by advanced algorithmic progress and comprehensive data, the VS has gained fast momentum in drug discovery paradigm. The VS protocol is performed predominantly by using the ligand-based (LB) and structure-based (SB) VS methods with each one having its own merits and demerits. The LBVS method works on the similarity approach based on the physicochemical parameters, chemical functionality, and shape similarity of the ligands. The SBVS method works on the complementarity of the ligand with the target binding site and is more preferred than LBVS due to the consideration of both ligand and target information. Further in the SBVS, the available conformational information of the active chemical space helps in making reasonable decisions for the ligand selection. However, the limitations in scoring functions and incorrect pose prediction may result in the inaccurate SB models of limited performance in VS experiments. Various factors interplay in the development of successful VS models and the fine tuning of these factors leads to the efficient VS models with high sensitivity. In this chapter, some of the recent ligand- and structure-based approaches for virtual screening in drug discovery are described.